Targeting Angiopoietin-2 to treat arteriovenous malformations in a genetic disorder
Angiopoietin-2 Signaling Targeted Therapeutics for Arteriovenous Malformations
This study is looking at how a protein called angiopoietin-2 affects blood vessel problems in people with Hereditary Hemorrhagic Telangiectasia (HHT), and it aims to find a way to reduce these issues to help make life easier for those living with HHT.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tulane University of Louisiana NIH-funded |
| Lab location | 1 site (New Orleans, United States) |
| Project ID | NIH-11049196 on NIH RePORTER |
What this research studies
This research focuses on Hereditary Hemorrhagic Telangiectasia (HHT), a genetic disorder that leads to the formation of fragile connections between arteries and veins, known as arteriovenous malformations (AVMs). The study investigates the role of angiopoietin-2, a protein that is elevated in HHT patients, in causing these vascular issues. By neutralizing angiopoietin-2, the researchers aim to reduce the severity of AVMs and associated complications in preclinical models. The ultimate goal is to develop a therapeutic approach that could alleviate the dangerous symptoms of HHT for affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Hereditary Hemorrhagic Telangiectasia who experience arteriovenous malformations.
Not a fit: Patients without Hereditary Hemorrhagic Telangiectasia or those not experiencing arteriovenous malformations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that significantly reduces the risk of severe complications from arteriovenous malformations in HHT patients.
How similar studies have performed: Previous research has shown promising results in targeting angiopoietin-2 for vascular disorders, suggesting potential success for this approach in HHT.
Where this research is happening
New Orleans, United States
- Tulane University of Louisiana — New Orleans, United States (Active)
Researchers
- Principal investigator: Meadows, Stryder Medoah — Tulane University of Louisiana
- Study coordinator: Meadows, Stryder Medoah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.